SUNESIS PHARMACEUTICALS INC (38)

Browse by Contract Category

Contracts

First Amendment to Loan and Security Agreement between the Registrant. and Silicon Valley Bank, dated as of August 26, 2022 (Filed With SEC on November 10, 2022)
Separation Agreement and Release by and between the Company and Ivor Royston, dated September 15, 2022 (Filed With SEC on September 19, 2022)
Mutual Termination Agreement, by and between Viracta Subsidiary, Inc. and Shenzhen Salubris Pharmaceutical Co. Ltd (Filed With SEC on August 23, 2021)
Open Market Sale AgreementSM, dated May 28, 2021, by and between Viracta Therapeutics, Inc. and Jefferies LLC (Filed With SEC on May 28, 2021)
Agreement and Plan of Merger and Reorganization, dated November 29, 2020, by and among Sunesis Pharmaceuticals, Inc., Sol Merger Sub, Inc. and Viracta Therapeutics, Inc (Filed With SEC on November 30, 2020)
Amended and Restated License Agreement, dated December 13, 2019, by and between the Registrant and Millennium Pharmaceuticals, Inc (Filed With SEC on March 10, 2020)
Executive Employment Agreement by and between the Company and Mark Rothera, dated September 15, 2022 (Filed With SEC on September 19, 2022)
2022 Employee Stock Purchase Plan (Filed With SEC on June 8, 2022)
Executive Incentive Compensation Plan (Filed With SEC on March 17, 2022)
Loan and Security Agreement, dated November 4, 2021, by and among Viracta Therapeutics, Inc., Viracta Subsidiary, Inc., Silicon Valley Bank and Oxford Finance LLC (Filed With SEC on November 10, 2021)
Amendment to Employment Agreement between Viracta Therapeutics, Inc. and Ivor Royston, M.D., dated August 12, 2021 (Filed With SEC on August 12, 2021)
2021 Inducement Equity Incentive Plan and form of agreement thereunder (Filed With SEC on August 12, 2021)
Amendment to Employment Agreement between Viracta Therapeutics, Inc. and Daniel Chevallard, dated August 12, 2021 (Filed With SEC on August 12, 2021)
Amendment to Employment Agreement between Viracta Therapeutics, Inc. and Lisa Rojkjaer, M.D., dated August 12, 2021 (Filed With SEC on August 12, 2021)
First Amendment to Loan and Security Agreement between Viracta Subsidiary, Inc. and Silicon Valley Bank, dated as of May 27, 2021 (Filed With SEC on May 28, 2021)
Royalty Purchase Agreement by and between the Registrant and XOMA (US) LLC, dated March 22, 2021 (Filed With SEC on May 13, 2021)
Amended and Restated Outside Director Compensation Plan (Filed With SEC on May 13, 2021)
Description of Capital Stock (Filed With SEC on February 24, 2021)
Form of Executive Severance Benefits Agreement between Sunesis Pharmaceuticals, Inc. and certain officers (Filed With SEC on December 22, 2020)
Form of Retention Benefits Letter between Sunesis Pharmaceuticals, Inc. and certain officers (Filed With SEC on November 30, 2020)
Form of Lock-Up Agreement, dated November 29, 2020 (Filed With SEC on November 30, 2020)
Form of Sunesis Pharmaceuticals, Inc. Support Agreement, dated November 29, 2020 (Filed With SEC on November 30, 2020)
Form of Viracta Therapeutics, Inc. Support Agreement, dated November 29, 2020 (Filed With SEC on November 30, 2020)
Executive Severance Benefits Agreement, dated May 4, 2020, by and between the Registrant and Tina Gullotta (Filed With SEC on August 11, 2020)
Consulting Agreement, dated May 2, 2020, by and between the Registrant and William P. Quinn (Filed With SEC on August 11, 2020)
Underwriting Agreement relating to the Offering, dated July 29, 2020 (Filed With SEC on July 31, 2020)
Deferral Agreement, dated April 2, 2020, by and between the Registrant and Silicon Valley Bank (Filed With SEC on May 7, 2020)
Description of Capital Stock (Filed With SEC on May 7, 2020)
Sunesis Pharmaceuticals, Inc. 2020 Bonus Program (Filed With SEC on February 14, 2020)
Form of Specimen Series F Preferred Stock Certificate (Filed With SEC on July 12, 2019)
Underwriting Agreement relating to the Series F Offering, dated July 10, 2019 (Filed With SEC on July 12, 2019)
Underwriting Agreement relating to the Common Stock Offering, dated July 10, 2019 (Filed With SEC on July 12, 2019)
Term Loan Agreement, dated April 26, 2019, by and between Sunesis Pharmaceuticals, Inc. and Silicon Valley Bank (Filed With SEC on April 29, 2019)
Second Amended and Restated Collaboration Agreement, dated December 16, 2013, by and between the Registrant and Biogen MA Inc (Filed With SEC on March 7, 2019)
Sunesis Pharmaceuticals, Inc. 2019 Bonus Program (Filed With SEC on February 4, 2019)
Underwriting Agreement relating to the Series E Offering, dated January 17, 2019 (Filed With SEC on January 22, 2019)
Form of Specimen Series E Preferred Stock Certificate (Filed With SEC on January 22, 2019)
Underwriting Agreement relating to the Common Stock Offering, dated January 17, 2019 (Filed With SEC on January 22, 2019)